ViaCell and Centocor seal cardiac deal
This article was originally published in Clinica
ViaCell has teamed up with Johnson & Johnson (J&J) firm Centocor to assess in preclinical trials its proprietary cord blood-derived multi-potent stem cells as a treatment for cardiac disease.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.